ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Hyundai Bioscience (048410.KQ)
Hyundai Bioscience stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · KOSDAQ · South Korea
₩5,820▼ -2.02%
Prices as of Oct 27, 2026 · KRW
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Hyundai Bioscience in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Hyundai Bioscience
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Hyundai Bioscience a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₩5,040 and ₩6,498; in 9 out of 10, between ₩4,024 and ₩8,140. Estimated annual volatility is 74%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₩575B
- Market cap (USD)
- $433M
- 52-week high
- ₩21,500
- 52-week low
- ₩4,565
- Revenue (12 months)
- ₩3.3B
- Net margin
- 0.0%
- Beta
- 0.92
What this means
ATLAS does not publish a fair value for 048410.KQ right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks 048410.KQ has traded between ₩4,565 and ₩21,500. Today it is 72.9% below that high and 27% above its low.
Its beta is 0.92: it moves roughly in line with the market.
About the company
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19.
Want to see everything about Hyundai Bioscience?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Hyundai Bioscience do?
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19.
What is the chance 048410.KQ goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, 048410.KQ ends the month between ₩5,040 and ₩6,498.
How big is Hyundai Bioscience and what is its P/E ratio?
Hyundai Bioscience's market capitalization is ₩575B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is 048410.KQ?
ATLAS estimates annual volatility at 74%. In a typical month, half of the outcomes end between ₩5,040 and ₩6,498.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer